Pleased to share that KAHF Biotech, Inc. has announced the filing of patent-pending technology supporting its next-generation therapeutic platform focused on the development of novel cancer therapeutics and diagnostics. The company’s platform-based intellectual property portfolio encompasses a broad range of therapeutic and diagnostic modalities designed to target critical drivers of tumor progression, metastatic disease, and treatment resistance across solid and hematological tumors.
The portfolio includes first-in-class approaches spanning antibody-drug conjugates (ADCs), T cell engager, Monoclonal Antibody, CAR-T cell therapies, antibody-oligonucleotide conjugates (AOCs), degrader-antibody conjugates (DACs), DsiRNA-based therapeutics, targeted biologics, companion diagnostics, and additional precision oncology applications. The platform is designed to support the development of multiple therapeutic strategies across diverse cancer indications while enabling future expansion into combination therapies and translational diagnostic technologies.
This patent-pending platform represents an important milestone in KAHF Biotech’s mission to advance innovative therapeutic approaches for patients with aggressive cancers. We believe the breadth of this platform provides significant opportunities for future therapeutic development, strategic partnerships, and translational research.
KAHF Biotech continues to advance preclinical research and platform development efforts focused on translating emerging scientific discoveries into targeted oncology therapeutics.
“Our vision is to revolutionize cancer treatment particularly metastatic disease by developing impactful, effective, and affordable therapies that are accessible to cancer patients worldwide. We aim to overcome the current challenges of metastatic disease and ensure that groundbreaking treatments reach those who need them most, no matter where they are.”
Muhammad Sadeqi Nezhad, Ph.D.
Founder & Chief Executive Officer
KAHF Biotech, Inc.
May 2026
KAHF Biotech, Inc. has successfully raised its initial seed round at a $10 million valuation cap, fully compliant with U.S. Securities and Exchange Commission (SEC) regulations.
This funding will support the development of our Innovative therapeutic monoclonal antibody, advancing the identification and optimization of lead mAbs for Investigational New Drug (IND)-enabling studies. This milestone positions KAHF Biotech to reach the IND stage and transition toward clinical development.
Our lead program targets pancreatic ductal adenocarcinoma (PDAC), with follow-on indications in colorectal cancer, ovarian cancer, and other solid tumors. We are specifically aiming to address one of the greatest unmet needs in oncology: cancer metastasis.
In parallel, we are expanding into next-generation modalities, including Antibody-Drug Conjugates (ADCs), Antibody Intracellular Delivery Conjugate (AIDC), and Degrader Antibody Conjugates (DACs), as we continue to push the frontiers of targeted cancer therapeutics.
We are deeply grateful to our early supporters and investors for believing in KAHF Biotech’s mission. Most importantly, we want to acknowledge our incredible team-your dedication, scientific rigor, and relentless commitment to advancing therapies for patients are what make milestones like this possible.
Muhammad Sadeqi Nezhad, Ph.D.
Founder & Chief Executive Officer
KAHF Biotech, Inc.
March 2026
